Genes, Patents, and Big Business: at 23andMe, are you the Customer or the Product?
By Adrianne Jeffries,
The Verge
| 12. 12. 2012
Ethical questions swirl as the personal genetics company starts scaling up
It’s been six years since DNA testing service
23andMe launched. In that time, about 180,000 people around the world have sent their saliva to the Mountain View-based company to test for more than 200 genetic traits and markers.
That’s not an inconsequential number, but it shows that personal DNA testing just isn’t a very large market yet. As a result, 23andMe has decisively shifted its focus to building and monetizing a giant database of genetic information, rather than satisfying personal curiosity. We’re entering the era of personal genetics as big business.
The company announced yesterday that it has raised
$50 million from name-brand investors including Google Ventures and Russian billionaire Yuri Milner to do just that. 23andMe is run by Anne Wojcicki, who is a 10-year veteran of healthcare investing and the wife of Google cofounder Sergey Brin; she and her husband both plunked down cash as well.
It’s been a big year for the personal genetics industry. Last week, personal genetics testing provider deCODE Genetics was bought by biotech company Amgen for $415 million. Genetics diagnostics startup Navigenics was...
Related Articles
By World Health Organization, World Health Organization | 11.20.2024
By Jim Thomas, Scan the Horizon | 11.19.2024
It’s the wee hours of 2nd November 2024 in Cali, Colombia. In a large UN negotiating hall Colombian Environment Minister Susana Muhamed has slammed down the gavel on a decision that should send a jolt through the AI policy world. ...
By Ned Pagliarulo, BioPharmaDive | 11.05.2024
A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial test, developer Beam Therapeutics said Tuesday. But the death of a trial participant could renew concerns about an older...
By Bill Newman and Demetra Georgiou, The Guardian | 11.03.2024